Insights

A&M Newsletters
Comprehensive and timely perspectives, on the topics that matter to you, sent straight to your inbox.
Created
Thought Leadership

Section 232 Pharmaceutical Duties: UK Rate Cut to Zero, and the Origin and Section 301 Questions That Follow

August 5, 2026
Effective July 31, 2026, the additional Section 232 tariff on patented pharmaceuticals that are products of the United Kingdom was reduced from 10% to zero (heading 9903.04.63), implementing the U.S.–UK Pharmaceutical Pricing Arrangement. Because UK patented pharmaceuticals remain subject to Section 232 (at a 0% rate), they also fall within the Section 232 carve-out from the new Section 301 forced labor tariffs — so qualifying UK patented product should face no additional duty under either regime.
Thought Leadership

Better Data, Better Exits: The New Playbook for Wealth and Insurance Platform Roll-Ups

August 5, 2026
There’s a new value creation imperative for private equity (PE) firms and corporates seeking to roll up financial technology (FinTech) and data platform acquisitions, especially in the extended higher interest rate environment. Many of the traditional value enhancement strategies still matter, but operational platforming—integrating tech, data, and systems—can be a defining competitive advantage in roll-ups.
Thought Leadership

The New Nuclear Delivery Model: How AI Can Drive Efficiency and Transparency and Accountability

August 4, 2026
This article explores how AI can transform nuclear project delivery. While AI is reshaping project planning, execution, and risk management, lasting success will depend on combining AI-powered project intelligence with governance models that clearly define accountability, enable faster decision-making, and create repeatable delivery frameworks for future projects.

How Service Providers Are Supporting Retail Alternative Products

August 4, 2026
Gautham Ratnakar, MD is joined by Nick Ablahani, MD, Head of Retail Alternative Products, and Lance Christofferson, SVP, Head of Product and Strategy, at Ultimus Fund Solutions to discuss the trends shaping the next phase of growth in retail alternatives.